VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation
about
Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel DiseaseFostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join ForcesSphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel DiseasePost-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation.Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacyProbiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinaseS1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancerAlternative medicines as emerging therapies for inflammatory bowel diseases.Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.The enterocyte microvillus is a vesicle-generating organelleThe gut microbiota and inflammatory bowel disease.Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.Space Environmental Factor Impacts upon Murine Colon Microbiota and Mucosal Homeostasis.Production Conditions Affect the In Vitro Anti-Tumoral Effects of a High Concentration Multi-Strain Probiotic Preparation.Importance of disrupted intestinal barrier in inflammatory bowel diseases.Physiological functions and clinical implications of sphingolipids in the gut.Lessons from probiotic-host interaction studies in murine models of experimental colitis.The role of probiotics and prebiotics in inducing gut immunity.A systematic review of the safety of probiotics.Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children.Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis.Clinical Evidence for the Microbiome in Inflammatory Diseases.How bacteria-induced apoptosis of intestinal epithelial cells contributes to mucosal inflammation.Understanding the canine intestinal microbiota and its modification by pro-, pre- and synbiotics - what is the evidence?Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3.Effect of fermented vegetable beverage containing Pediococcus pentosaceus in patients with mild to moderate ulcerative colitis.
P2860
Q26741117-2252F84B-3E9E-48E9-9297-5B4888E59E43Q26765948-C7DE8AC6-FD86-461B-A829-980EC128E83AQ28073700-B3DF49C5-48E0-4795-BBBF-91F4121E6C94Q33406281-63B7B013-4524-43A9-8475-2FBC6708D9F7Q33503647-7799C310-1B6E-4B28-9779-659331F5FB84Q33847243-2DD91692-28E6-4A07-BAE6-88367CBD3278Q33857794-5850859A-9AC4-4EE7-AF19-C27E58EEF66AQ34069427-7FEF7B44-D02C-457E-A5D1-DE26FFF2D4FAQ34637606-7F6CC950-BD35-4549-9B6B-2FE80C0DB1E2Q34989756-3F92F51F-61E4-4DCE-BF6A-16977775916BQ35446516-1E7F3D79-4043-4877-BDA6-D2F3641F8260Q35601294-2046758A-747C-414F-8834-5736495D754FQ35665962-EC6F2FD0-A417-4180-9862-A67ED1561B95Q36140994-B3268BF1-6C53-4329-BD94-5B5D516D1157Q37781315-ADEE698E-CDC1-42CF-B2D9-588444CCCC3AQ37852814-B6008795-9181-467E-BE9D-144575D7ADCEQ37907198-F0E9B43A-BBD7-47E5-ADD1-B8B1C7FFE1EAQ38174603-C9F95F67-260D-40C0-A6C4-248F7207723DQ38176954-CA6ACA66-342D-49FD-8078-AA79C2AE8064Q38267662-10C469FE-6397-4547-975D-B97C56DC89DAQ39014759-9F903C89-4223-4850-BA76-914C8980AFBAQ39265428-525DB22C-6315-42DD-B831-CCADD317BE32Q41216095-BDF25035-767E-4CAF-999B-24141143D9D4Q42657761-22AD0E0F-8940-4FC3-A099-9478F48DF9AAQ46143449-B6343992-F943-458A-A716-31B39FCA57F3Q53575927-24147AE6-04D3-4F91-94C1-394B331A4DA1Q55317992-0FB111F9-64A4-4557-82B2-FBDBC7203258
P2860
VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@ast
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@en
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@nl
type
label
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@ast
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@en
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@nl
prefLabel
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@ast
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@en
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@nl
P2093
P2860
P3181
P356
P1476
VSL#3 probiotic upregulates in ...... inase and reduces inflammation
@en
P2093
B C Sydora
C Desimone
K L Madsen
L Di Marzio
R N Fedorak
R Sherbaniuk
P2860
P304
P3181
P356
10.1155/2008/520383
P407
P577
2008-03-01T00:00:00Z